Exelixis (EXEL) vs Neurocrine Biosciences (NBIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Exelixis (EXEL) has outperformed Neurocrine Biosciences (NBIX) over the past year, gaining 52.0% versus a gain of 6.2%. Over five years, EXEL leads with a +278.8% price change compared with +73.1% for NBIX. Exelixis is the larger company by market cap ($15.77 billion vs $15.24 billion), about 1.0 times the size, while Neurocrine Biosciences is growing revenue faster (+21.4% vs +7.0%).
On valuation, Neurocrine Biosciences trades at a lower forward P/E (12.2x vs 15.1x for Exelixis). Exelixis converts more of its revenue into profit, with a net margin of 33.7% versus 16.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EXEL | NBIX |
|---|---|---|
| Share price | $64.63 | $150.57 |
| Market cap | $15.77B | $15.24B |
| 1-day change | -1.82% | -3.84% |
| YTD return | +47.46% | +6.16% |
| 1-year return | +52.03% | +6.16% |
| 5-year return | +278.84% | +73.11% |
| P/E ratio (TTM) | 19.35 | 22.34 |
| Forward P/E | 15.12 | 12.24 |
| EPS (TTM) | $3.34 | $6.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.32B | $2.86B |
| Revenue growth (YoY) | +6.98% | +21.45% |
| Net income (latest FY) | $782.57M | $478.60M |
| Gross margin | 96.39% | 98.18% |
| Operating margin | 37.59% | 21.64% |
| Net margin | 33.73% | 16.73% |
| 52-week high | $73.69 | $186.12 |
| 52-week low | $39.71 | $122.14 |
| Distance from 52-week high | -12.29% | -19.10% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | -4.73% | +38.50% |
| Average volume | 2.45M | 1.34M |
| Shares outstanding | 244.01M | 101.22M |
| Employees | 1,077 | 2,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EXEL has outperformed NBIX by 45.9 percentage points over the past year.
- Exelixis is more profitable, keeping 33.7 cents of every revenue dollar as net income versus 16.7 cents for Neurocrine Biosciences.
- Neurocrine Biosciences grew revenue faster in its latest fiscal year (+21.45% vs +6.98%).
About Exelixis
EXEL stock →Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,077 employees
About Neurocrine Biosciences
NBIX stock →Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees
EXEL vs NBIX FAQ
Which is bigger, Exelixis or Neurocrine Biosciences?
Exelixis (EXEL) is larger, with a market capitalization of $15.77B compared with $15.24B for Neurocrine Biosciences (NBIX).
Which stock has performed better over the past year, EXEL or NBIX?
EXEL returned +52.03% over the past 12 months, compared with +6.16% for NBIX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, EXEL or NBIX?
EXEL has the lower trailing P/E at 19.4, versus 22.3 for NBIX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Exelixis and Neurocrine Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.